|Table of Contents|

Impact of ASXL1 mutated sites and co-mutated genes on the prognosis of patients with myeloid neoplasms

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 14
Page:
2585-2590
Research Field:
Publishing date:

Info

Title:
Impact of ASXL1 mutated sites and co-mutated genes on the prognosis of patients with myeloid neoplasms
Author(s):
WEI Zixiu1; CHENG Juan2
1.The First School of Clinical Medicine,Lanzhou University,Gansu Lanzhou 730000,China;2.Department of Hematology,the First Hospital of Lanzhou University,Gansu Lanzhou 730000,China.
Keywords:
ASXL1 mutation; co-mutated genes; myeloid neoplasms
PACS:
R733
DOI:
10.3969/j.issn.1672-4992.2024.14.016
Abstract:
Objective:To investigate the impact of ASXL1 mutated sites and co-mutated genes on the prognosis of myeloid neoplasms.Methods:The cBioportal database was searched and screened for mutation and clinical data of patients with myeloid neoplasms ［acute myeloid leukemia (AML),myelodysplastic syndrome (MDS),chronic myelomonocytic leukemia(CMML)］,including data of 290 patients with ASXL1 mutation.94 patients with ASXL1 mutations admitted to our hospital from January 2016 to June 2023 with primary diagnosis of AML,MDS,CMML patients were collected,which were merged with the data of 290 cases screened in the database.Excel,SPSS 25.0 and R4.3.1 software were applied to analyze the statistics.Results:The proportions of concomitant SRSF2,RUNX1,STAG2,CBL,and IDH2 co-mutations in the ASXL1G646 group were higher than those in the ASXL1other group,and only RUNX1 co-mutations showed a statistically significant difference between the two groups ［35.7%(41/115) vs 20.4%(55/269),P=0.002］.TET2 was mutated in a higher proportion of AML patients than in MDS and CMML(50.8% vs 30.8% vs 48.6%,P=0.001),and STAG2 and SF3B1 were mutated in the highest proportion in MDS(STAG2:6.2% vs 19.4% vs 9.7%,P=0.010.SF3B1:1.5% vs 17.8% vs 4.2%,P=0.000),and SRSF2 had the highest proportion of mutations in CMML(29.2% vs 27.9% vs 45.8%,P=0.015),the difference was statistically significant.Multivariate analysis showed that age≥68 years old,RUNX1 co-mutation,and STAG2 co-mutation were all independent risk variables that had an impact on the prognosis of myeloid neoplasms patients with ASXL1 mutation.The overall survival (OS) of patients in the ASXL1G646 group were slightly shorter than those in the ASXL1other group,but the difference was not statistically significant.Conclusion:ASXL1 mutation sites has no significant effect on the prognosis of myeloid neoplasms patients,at the initial diagnosis,age≥68 years old,RUNX1 co-mutation,and STAG2 co-mutation are the independent risk factors affecting the OS of myeloid neoplasms patients with ASXL1 mutation.

References:

［1］ PASCHKA P,SCHLENK RF,GAIDZIK VI,et al.ASXL1 mutations in younger adult patients with acute myeloid leukemia:a study by the German-Austrian Acute Myeloid Leukemia Study Group［J］.Haematologica,2015,100(3):324-330.
［2］ 贾闻博，刘金婷，杨新雨，等.伴ASXL1基因突变初诊急性髓系白血病患者的临床特征及生存分析［J］.中华血液学杂志，2022,43(10):833-840. JIA WB,LIU JT,YANG XY,et al.Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation［J］.Chinese Journal of Hematology,2022,43(10):833-840.
［3］ MAURYA N,MOHANTY P,DHANGAR S,et al.Comprehensive analysis of genetic factors predicting overall survival in myelodysplastic syndromes［J］.Sci Rep,2022,12(1):5925.
［4］ GUGLIELMELLI P,COLTRO G,MANNELLI F,et al.ASXL1 mutations are prognostically significant in PMF,but not MF following essential thrombocythemia or polycythemia vera［J］.Blood Adv,2022,6(9):2927-2931.
［5］ 谭雅娴，许娜，黄继贤，等.108例骨髓增殖性肿瘤患者基因突变与临床特征分析［J］.中华血液学杂志，2020,41(7):576-582. TAN YX,XU N,HUANG JX,et al.Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm.［J］.Chinese Journal of Hematology,2020,41(7):576-582.
［6］ NIE Y,SHAO L,ZHANG H,et al.Mutational landscape of chronic myelomonocytic leukemia in Chinese patients［J］.Exp Hematol Oncol,2022,11(1):32.
［7］ CERAMI E,GAO J,DOGRUSOZ U,et al.The cBio cancer genomics portal:an open platform for exploring multidimensional cancer genomics data［J］.Cancer Discov,2012,2(5):401-404.
［8］ GAO J,AKSOY BA,DOGRUSOZ U,et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal［J］.Sci Signal,2013,6(269):pl1.
［9］ YU J,LI Y,LI T,et al.Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia［J］.Experimental Hematology & Oncology,2020,9(1):2.
［10］ LACHOWIEZ CA,LONG N,SAULTZ J,et al.Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia［J］.Blood Advances,2023,7(9):1899-1909.
［11］ JOHNSON SM,HABERBERGER J,GALEOTTI J,et al.A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease［J］.Blood Cancer Journal,2023,13(1):96.
［12］ BALUSU R,MONTES-MORENO S,ROUTBORT MJ,et al.Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era［J］.Plos One,2018,13(9):e0204218.
［13］ FRIEDRICH C,ZALMAI L,GAY J,et al.PCR-Fluo-ASXL1-FA:A fast,sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies［J］.International Journal of Laboratory Hematology,2022,44(5):928-933.
［14］ WU P,WENG J,LI M,et al.Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs［J］.American Journal of Translational Research,2019,11(6):3651-3658.
［15］ PARSA-KONDELAJI M,AYATOLLAHI H,ROSTAMI M,et al.Evaluating the frequency,prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran［J］.Journal of Cellular and Molecular Medicine,2022,26(13):3797-3801.
［16］ BERA R,CHIU MC,HUANG YJ,et al.RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia［J］.Journal of Hematology & Oncology,2019,12(1):104.
［17］ THOTA S,VINY AD,MAKISHIMA H,et al.Genetic alterations of the cohesin complex genes in myeloid malignancies［J］.Blood,2014,124(11):1790-1798.
［18］ ECKARDT JN,STASIK S,ROLLIG C,et al.Alterations of cohesin complex genes in acute myeloid leukemia:differential co-mutations,clinical presentation and impact on outcome［J］.Blood Cancer Journal,2023,13(1):18.
［19］ FAN Y,LIAO L,LIU Y,et al.Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia［J］.Cancer Cell Int,2021,21(1):526.
［20］ 陈梅玉，刘洁，晁红颖，等.骨髓增生异常综合征患者的ASXL1基因变异分析［J］.中华医学遗传学杂志，2020,37(2):110-115. CHEN MY,LIU J,CHAO HY,et al.Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome［J］.Chinese Journal of Medical Genetics,2020,37(2):110-115.
［21］ CUI Y,TONG H,DU X,et al.TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemia［J］.Stem Cell Investig,2016,3:50.

Memo

Memo:
甘肃省药品科研项目（编号：2021GSMPA009）
Last Update: 1900-01-01